Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

A protocol designed for primary care increased weight loss across a quarter of a million people, but only 25% of those with a ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

Patients with obesity can now get Zepbound’s strongest doses for a flat rate through Lilly’s self-pay pharmacy.

Novo Nordisk has presented full Phase 3 trial results for CagriSema, an experimental weight-loss drug, revealing primarily ...